Compensation of the 1100delC defect in CHK2 by CHK1, or any other mechanism, might explain the rather low breast cancer risk associated with the CHEK2 variant, compared to that associated with truncating mutations in BRCA1 or BRCA2. This evidence concerns the gene BRCA2 and breast carcinoma.